Abstract: An optical element driving mechanism is provided and includes a fixed assembly, a movable assembly, a driving assembly and a stopping assembly. The fixed assembly has a main axis. The movable assembly is configured to connect an optical element, and the movable assembly is movable relative to the fixed assembly. The driving assembly is configured to drive the movable assembly to move relative to the fixed assembly. The stopping assembly is configured to limit the movement of the movable assembly relative to the fixed assembly within a range of motion.

Abstract: A wireless communications circuit and an associated wireless communications device are provided. The wireless communications circuit may include a power amplifier with integrated filter (PAMiF) module and a two-stage switch module, and the two-stage switch module may include a first switch and a second switch. For example, a first port of the first switch is coupled to a filter port of the PAMiF module, and a second port of the first switch at an opposite side to the first port of the first switch is coupled to a first antenna. In addition, a first port of the second switch is coupled to a third port of the first switch at the opposite side to the first port of the first switch, and a second port of the second switch is coupled to a second antenna.

Abstract: A wireless communications circuit and an associated wireless communications device are provided. The wireless communications circuit may include a power amplifier with integrated filter (PAMiF) module and a two-stage switch module, and the two-stage switch module may include a first switch and a second switch. For example, a first port of the first switch is coupled to a filter port of the PAMiF module, and a second port of the first switch at an opposite side to the first port of the first switch is coupled to a first antenna. In addition, a first port of the second switch is coupled to a third port of the first switch at the opposite side to the first port of the first switch, and a second port of the second switch is coupled to a second antenna.

Abstract: Zhankuic acid A (ZAA) is the major pharmacologically active compound of Taiwanofungus camphoratus. We analyzed the structure of human TLR4/MD-2 complex with ZAA by X-score and HotLig modeling approaches. Two antibodies against MD-2 were used to verify the MD-2/ZAA interaction. The inflammation and survival of the mice pretreated with ZAA and injected with LPS were monitored. The modeling structure shows that ZAA binds the MD-2 hydrophobic pocket exclusively via specific molecular recognition; the contact interface is dominated by hydrophobic interactions. Binding of ZAA to MD-2 reduced antibody recognition to native MD-2, similar to the effect of LPS binding. Furthermore, ZAA significantly ameliorated LPS-induced endotoxemia and Salmonella-induced diarrhea in mice. Our results indicate that ZAA, which can compete with LPS for binding to MD-2 as a TLR4/MD-2 antagonist, is a potential therapeutic agent for Gram-negative bacterial infections.

Abstract: Zhankuic acid A (ZAA) could suppress phosphorylation of JAK2 and JAK3 and signaling of downstream molecules. Moreover, ZAA could inhibit the IFN-?/STAT1/IRF-1 pathway in vivo and in vitro. Furthermore, data show that pre-treatment with ZAA could significantly ameliorate Con A-induced hepatitis in mice. The above results strongly suggest that ZAA treatment could block JAK2 and JAK3 activation, and may be a valuable therapeutic approach for the treatment of immune cell induced inflammation.

Abstract: The present invention relates to a process for preparing water-soluble and dispersed iron oxide (Fe3O4) nanoparticles and application thereof, characterized in which two-stage additions of protective agent and chemical co-precipitation are employed in the process. In the first stage, Fe3O4 nanoparticles are obtained using absorbent-reactant coexistence technology. In the second stage, proper amount of adherent is added to cover the nanoparticle surface entirely. The resulting water-soluble and dispersed Fe3O4 nanoparticles can easily bind with thiols or biomolecules, such as nucleic acid and peptide. The Fe3O4 nanoparticles of the present invention may be used as magnetic resonance imaging contrast agent and used in magnetic guiding related biomolecular technologies for clinical testing, diagnosis and treatment.

Abstract: The present invention relates to a process for preparing water-soluble and dispersed iron oxide (Fe3O4) nanoparticles and application thereof, characterized in which two-stage additions of protective agent and chemical co-precipitation are employed in the process. In the first stage, Fe3O4 nanoparticles are obtained using absorbent-reactant coexistence technology. In the second stage, proper amount of adherent is added to cover the nanoparticle surface entirely. The resulting water-soluble and dispersed Fe3O4 nanoparticles can easily bind with thiols or biomolecules, such as nucleic acid and peptide. The Fe3O4 nanoparticles of the present invention may be used as magnetic resonance imaging contrast agent and used in magnetic guiding related biomolecular technologies for clinical testing, diagnosis and treatment.